We are live on ! Find out more

Neurocrine Biosciences

NBIX

Market cap $16B

157.22 USD

+1.00

0.64%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

157.22

0.00

0%

1 day

0.64%

5 days

2.1%

1 month

2.95%

3 months

-1.44%

6 months

21.08%

Year to date

11.82%

1 year

11.95%

5 years

66.16%

10 years

205.1%

About: Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Employees: 2,500

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 54.5%

Neutral 38.6%

Negative 6.8%

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

Zacks Investment Research

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

Zacks Investment Research

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine Biosciences: 'House Full Of Options'

Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation.

Neurocrine Biosciences: 'House Full Of Options'

Zacks Investment Research

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?

Zacks Investment Research

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Zacks Investment Research

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

Zacks Investment Research

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

See News Rankings

Price charts implemented using Lightweight Charts™